VCCT

Vascular Cell Therapy (VCCT) is a biotechnology company focused on developing regenerative cell therapies for vascular diseases. The company utilizes a proprietary platform to generate high-purity endothelial cells from induced pluripotent stem cells (iPSCs) to restore blood flow in ischemic tissues. Its lead program, VCCT-01, is being developed for the treatment of peripheral artery disease (PAD) and critical limb ischemia (CLI). By providing a scalable source of functional vascular cells, VCCT aims to offer a transformative treatment option for patients with limited surgical or endovascular alternatives. The company's technology is based on research from the Houston Methodist Research Institute.